Listed by the USPTO as KARUNASENA, ENUSHA
Tech Center 1700 • Art Units: 1600 1632 1643 1645 1647 1651 1653 1796 1797
This examiner grants 33% of resolved cases
KARUNASENA, ENUSHA is a USPTO patent examiner in Tech Center 1700 and Art Unit 1600. The record contains 6 resolved cases, with a 33.3% allowance rate, a 100.0% interview lift, and a median of 1017 days to allowance. The limited sample makes the allowance and interview figures preliminary, although the record associates interviews with improved allowance outcomes.
The recurring companies are Honda Motor Co., Ltd., THE GENERAL HOSPITAL Corporation, and Nestlé S.A. The listed firms are FOLEY & LARDNER LLP, K&L Gates LLP-Nestec S.A., and AMIN, TUROCY & WATSON, LLP. Counsel may consider an interview where it can address a defined prosecution issue, but the 6-case record does not establish a stable pattern. The 1017-day median is best used as an initial timing reference rather than a prediction.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18555205 | DYNAMIC NUTRIENT CONTROL PROCESSES | Final Rejection | Janssen Biotech, Inc. |
| 18685934 | MICROALGAL CULTURE STATE DETERMINATION METHOD | Final Rejection | HONDA MOTOR CO., LTD. |
| 18726542 | CORYNEBACTERIUM TO TREAT OR LIMIT CUTANEOUS WOUND INFECTION | Non-Final OA | THE GENERAL HOSPITAL CORPORATION |
| 18692462 | METHOD FOR DETECTING AND/OR QUANTIFYING MOOD DISORDER AND/OR IMPROVEMENTS OF THE MOOD DISORDER STATUS USING BUTYRATE AS BIOMARKER AND IMPROVED METHODS AND COMPOSITIONS THEREOF | Non-Final OA | SOCIETE DES PRODUITS NESTLE S.A. |
| 18464152 | COMBINATION THERAPY FOR INFLAMMATORY DISEASES | Final Rejection | The United States Government, as Represented by the Department of Veterans Affairs |
| 18712230 | LIQUID CARRIER CONCENTRATE COMPRISING AT LEAST ONE BENEFICIAL MICROORGANISM AND USES THEREOF | Non-Final OA | SPECIALTY OPERATIONS FRANCE |
| 18482990 | COMPOSITIONS AND METHODS COMPRISING SERINE PROTEASE VARIANTS | Non-Final OA | Danisco US Inc. |
| 18704810 | AGENT FOR INHIBITING PROLIFERATION OF SARS-CoV-2 | Non-Final OA | Kirin Holdings Kabushiki Kaisha |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy33.3% of resolved applications examined by Enusha Karunasena were allowed (6 resolved cases), compared with 36.5% across Art Unit 1600 over the last five years.
This examiner's interview lift is +100.0 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Enusha Karunasena took 1,017 days on average from filing to allowance.
Enusha Karunasena examines applications in Art Unit 1600 in Tech Center 1700 (Chemistry & Materials).